Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects.

Richard VollenbergEva Ulla LorentzenJoachim KühnTobias Max NowackiJörn Arne MeierJonel TrebickaPhil-Robin Tepasse

Published in: Vaccines (2023)

Even after the third vaccination, immunosuppressed IBD patients exhibited diminished humoral immunity compared to healthy controls, especially those on anti-TNF therapy. Cases of penetrating infections led to considerably higher antibody levels in IBD patients under anti-TNF therapy compared to uninfected patients. Further investigation through prospective studies in immunosuppressed IBD patients is needed to determine whether this effectively safeguards against future infections or severe disease.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
sars cov
peritoneal dialysis
stem cells
mesenchymal stem cells
early onset
hiv infected